Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast, Inc. (NYSE: MED) generates a steady flow of news centered on its health and wellness programs, metabolic health strategy, and financial performance. As the company behind the OPTAVIA® lifestyle system and the Metabolic Synchronization™ framework, Medifast regularly issues updates that highlight how it is addressing obesity, lifestyle change, and the broader challenge of metabolic dysfunction.
Readers of this MED news page can expect coverage of quarterly and annual financial results, including trends in revenue, the number of independent active earning OPTAVIA coaches, and revenue per active earning coach. These releases often include commentary from leadership on business transformation, strategic priorities, and the company’s focus on metabolic health and long-term growth.
Medifast also publishes scientific and clinical news, such as research presented at conferences like ObesityWeek. These updates describe studies on topics including lean mass preservation on the Optimal Weight 5 & 1 Plan®, the long-term effects of anti-obesity medications, and links between sleep quality and metabolic outcomes. Such items illustrate how the company’s Scientific & Clinical Affairs team and Scientific Advisory Board contribute to evidence-based program development.
In addition, investors and observers will find corporate and strategic announcements, including the introduction of Metabolic Synchronization™, shifts in positioning from weight loss to metabolic health, and leadership or governance changes documented in press releases and related SEC filings. The company also highlights brand and educational initiatives, such as the “Health by Design” docuseries that explores cultural and environmental factors influencing metabolic health and longevity.
This news page is a central resource for following Medifast’s evolving approach to metabolic health, its OPTAVIA coach network, research milestones, and key corporate developments. For those tracking MED, it offers a consolidated view of how the company communicates its strategy, science, and financial trajectory over time.
Medifast (NYSE: MED) announced that OPTAVIA’s metabolic health system is now eligible for reimbursement on select insurance plans using HSA/FSA funds, potentially letting clients save up to 40% on program costs.
The company cites Metabolic Synchronization science and a clinical result showing 98% lean mass retained and a 14% reduction in visceral adiposity at 16 weeks, and plans a new product system launch in 2026.
Medifast (NYSE: MED) reported Q4 2025 revenue of $75.1M and full-year 2025 revenue of $385.8M, with Q4 net loss of $18.1M and full-year net loss of $18.7M. Cash and investment securities totaled $167.3M with no debt. Active earning coaches declined to 16,100, while revenue per active coach rose to $4,664. The company established a $12.1M non-cash valuation allowance against deferred tax assets, which materially affected EPS.
Medifast provided 2026 revenue and EPS ranges and reinstated guidance as it executes a transformation toward metabolic health offerings.
Medifast (NYSE: MED) will announce financial results for the quarter and full year ended December 31, 2025, on Tuesday, February 17, 2026 after market close.
The company will host a conference call at 4:30 p.m. ET with CEO Dan Chard, President Nick Johnson, and CFO Jim Maloney. The call will be webcast and archived through May 17, 2026. Telephone and playback dial-in details are provided for listeners.
Medifast (NYSE: MED) highlighted Tiffany Howard’s metabolic health transformation with OPTAVIA after a People magazine feature on January 16, 2026. Tiffany credited OPTAVIA’s mix of science-backed nutrition, personalized coaching and community support for reversing metabolic dysfunction and achieving healthy weight loss while retaining lean mass.
The company cites a clinical study showing clients with OPTAVIA coaching achieved 10x greater weight loss, 17x more fat loss, 98% lean mass retention and a 14% reduction in visceral adiposity at 16 weeks. A commissioned survey found 94% of Americans worry about metabolic health and 85% believe reversal is possible.
Medifast (NYSE: MED) premiered the second episode of its OPTAVIA docuseries, “Health by Design: Spain”, which examines factors that support metabolic health and longevity in Galicia and Madrid. The episode, hosted by OPTAVIA co-founder Dr. Wayne Andersen and President Nicholas Johnson, highlights community, routine, activity, and diet as drivers of healthspan. The premiere was celebrated by thousands of independent coaches at Get America Healthy events on January 10, 2026.
Medifast (NYSE: MED) announced a planned leadership transition: Nicholas Johnson is appointed President effective immediately and is expected to succeed Dan Chard as Chief Executive Officer in June 2026. Dan Chard will remain Chairman of the Board after stepping down as CEO. The company said Johnson will work closely with Chard and the Board during a deliberate transition period. The announcement also notes that Tony Tyree, Chief Business Operations Officer, is leaving the company effective immediately. Johnson joined Medifast in 2018 and became Chief Field Operations Officer in 2022, having previously held leadership roles at Nu Skin.
Medifast (NYSE: MED) published OPTAVIA's report "Metabolic Health in America" (survey fielded Sep 23–29, 2025; n=1,004) showing 80% of U.S. adults lack understanding of metabolic health while 94% express concern about at least one related issue.
Key survey outcomes: 43% had heard the term, 65% report three+ metabolic concerns, 74% felt motivated to improve after learning the definition, and 85% believe metabolic dysfunction can be reversed. The release links these findings to Medifast's 2025 strategic shift to Metabolic Synchronization and cites a clinical study showing 14% visceral fat reduction and 98% lean mass retained at 16 weeks.
Medifast (NYSE:MED) presented new metabolic health research at ObesityWeek in Atlanta (Nov 4–7, 2025).
Two poster studies highlighted: a GLP‑1/dual agonist analysis showing a weight‑loss plateau after 96 weeks at the highest tirzepatide dose (15 mg) and a rebound in energy intake and weight after medication discontinuation; and a sleep analysis from Midlife in the United States linking poor sleep quality to higher long‑term odds of obesity (1.8×) and diabetes (2.5×) over ~12 years. Medifast reiterated its Oct 2025 strategy launch, Metabolic Synchronization™, and emphasized lifestyle integration (nutrition, behavioral support, self‑monitoring) alongside medical therapies.
Medifast (NYSE: MED) reported third quarter 2025 results with revenue $89.4M (down 36.2% YoY) and a net loss $2.3M (loss of $0.21 per diluted share). Active earning OPTAVIA coaches fell 35.0% to 19,500, driving lower sales; revenue per active coach was $4,585. Gross profit declined 41.2% to $62.2M and gross margin narrowed to 69.5%. SG&A decreased 36.0% to $66.2M but rose slightly as a percent of revenue to 74.1%. The company ended the quarter with a strong balance sheet: $173.5M cash and investments, no debt. Guidance: Q4 2025 revenue $65M–$80M and diluted loss per share $(0.70)–(1.25).
Medifast (NYSE: MED) announced a strategic shift to focus on metabolic health with the introduction of Metabolic Synchronization™, a clinical-backed system the company says reduces visceral fat, preserves lean mass and protects muscle.
Key data: a 14% reduction in visceral fat in 16 weeks and retention of 98% of lean mass reported in company research. Medifast plans new product launches using this science in 2026 and emphasizes coach-led programs and published clinical evidence supporting the approach.